Percheron Therapeutics Ltd (fra:AWY0) Share Price

Company Profile

Business description
Percheron Therapeutics Ltd is a clinical-stage biotechnology company advancing first-in-class immuno-oncology therapies to tackle some of the difficult-to-treat cancers. The company's product pipeline comprises the following drug candidates: avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor, and HMBD-002, a monoclonal antibody that has shown activity in a wide range of animal models of cancer and has shown evidence of synergy when combined with other immuno-oncology drugs such as Keytruda (pembrolizumab). Its operating segments are ATL1102, which generates maximum income, and HMBD-002.
Contact
35 Collins Street
Level 30, Collins Place
MelbourneVIC3000
AUS
T: +61 398278999
https://www.percherontx.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
Employees
8

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,782.82	28.44	-0.36%
DAX 40	25,181.65	190.10	-0.75%
Dow JONES (US)	52,259.05	608.93	-1.15%
FTSE 100	10,690.36	34.67	-0.32%
HKSE	23,093.37	158.69	0.69%
NASDAQ	25,961.71	47.15	-0.18%
Nikkei 225	62,693.16	214.68	-0.34%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,626.59	36.84	-0.48%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,690.48	32.45	0.89%